Best Treatment for Peyronie's Disease

The best treatment for Peyronie's disease depends on the phase of the disease, the severity of the penile curvature, and the trade-offs a man will accept — collagenase injections, traction therapy, and surgery each win different cases. No single option wins them all, yet each case has a best treatment. Every class of treatment options is judged below against its trial record: the AUA guideline as the consensus spine, then the trials behind it. The lanes run from watchful waiting through intralesional injection and oral therapy to penile traction therapy and reconstructive surgery, and you choose between them on evidence and case fit. Nothing here replaces a urologist's assessment of your phase and deformity.

Choosing a Peyronie's disease treatment is a case-fit decision, not a ranking exercise. Four criteria decide the choice: disease phase, the severity of the penile curvature, erectile function, and the invasiveness the patient will accept, from a worn traction device to an operation. How the mechanical lane acts on a fibrous plaque in the tunica albuginea, and how traction is supervised by phase, sits in the penile traction device for Peyronie's disease guide. What Peyronie's disease is and how it is diagnosed belongs to Peyronie's disease: causes, symptoms, and treatment. Each criterion is defined below.

1. Disease phase — acute (active) phase or chronic (stable) phase

The acute phase — plaque still forming, erections often painful — favours conservative and injection lanes; surgery waits for the chronic phase.

2. Curvature severity and deformity type

A mild curve that still allows intercourse is a different problem from a curve of 60 degrees or more, an hourglass narrowing, or a biplanar deformity: severity decides the options.

3. The trade-offs you will accept

Surgery corrects the most, with reported penile shortening and erectile-function risk; injection means cycle-based clinic visits; traction costs daily wear hours, where compliance decides the outcome.

4. The evidence grade behind the option

The AUA guideline scores each treatment's evidence A, B, or C with a Strong, Moderate, or Conditional recommendation

In short: you should have the curve measured and the phase confirmed by a urologist before choosing a lane.

Peer-reviewed evidence for Peyronie's disease treatment rests on one guideline and a short list of trials. Nehra and colleagues, for the American Urological Association (J Urol 2015, PMID 26066402), built the AUA guideline on a systematic review of 303 articles, grading each treatment A, B, or C with a Strong, Moderate, or Conditional recommendation. One scope note: the AUA document is the 2015 guideline, amended since, and every recommendation below is cited by its statement number. A wider guide to Peyronie's disease treatment options is planned. The classes below run in conventional clinical order, not as a league table — the only ranking that matters is chosen for a single case.

Intralesional collagenase clostridium histolyticum, marketed as Xiaflex, is the only drug the FDA has approved specifically for Peyronie's disease — an approval belonging to the medication; a traction device, by contrast, is FDA-registered, a listing status and not an efficacy finding. AUA Guideline Statement 8 permits intralesional collagenase with modeling for curvature reduction in stable disease: Moderate Recommendation, Grade B, the highest grade any treatment carries in this comparison. Gelbard and colleagues (J Urol 2013, PMID 23376148) reported IMPRESS I and II, two double-blind, randomized, placebo-controlled phase 3 trials in 417 and 415 men. In a pooled post hoc analysis, treated men improved a mean 34%, or −17.0 ± 14.8 degrees, against 18.2% and −9.3 ± 13.6 degrees on placebo (p<0.0001) — placebo moved too, so the effect is the gap between arms, roughly 7.7 degrees, not 17. Three men sustained a corporeal rupture requiring repair. Verdict: the strongest evidence in this comparison, scoped to stable disease inside the studied 30-to-90-degree range.

Interferon α-2b is the second injectable with placebo-controlled support. Hellstrom and colleagues (J Urol 2006, PMID 16753449) enrolled 117 men in a single-blind, placebo-controlled study, giving interferon α-2b at 5 × 10⁶ units biweekly for 12 weeks to the 55 in the treatment arm against 62 on saline: curvature, plaque size and density, and pain resolution improved significantly more than on placebo — significance published without a mean degree figure, so none is printed here. The AUA grades interferon Moderate on Grade C evidence (Statement 10), and Russo's network meta-analysis (J Sex Med 2019, PMID 30692028; 1,050 patients) put collagenase and interferon α-2b top for curvature among injectables, though it could not compare pain, plaque size or satisfaction. Verdict: real support, one grade below collagenase.

Intralesional verapamil has the weakest controlled evidence in this comparison. Shirazi and colleagues (Int Urol Nephrol 2009, PMID 19199072) randomized 80 men to intralesional verapamil or saline: curvature decreased in 17.5% of the verapamil group against 23.1% of controls (p=0.586) — proportions of men who improved, not degrees — and the authors "did not find any improvement in comparison with the control group." An earlier 14-patient single-blind study of intralesional verapamil by Rehman and colleagues (Urology 1998, PMID 9586617) found plaque volume down in 57% against 28% of controls (p<0.04), with a non-significant curvature change (37.71 to 29.57 degrees, p<0.07). Russo's 2019 network meta-analysis (PMID 30692028) ranked verapamil below collagenase and interferon α-2b. Verdict: the evidence does not support ranking verapamil on curvature efficacy — the AUA's Conditional Recommendation on Grade C evidence (Statement 12) is the honest frame; dosing belongs to the Peyronie's disease medication guide.

Oral therapy is the class the guideline settles outright: AUA Guideline Statement 6 instructs clinicians not to offer vitamin E, tamoxifen, procarbazine, omega-3 fatty acids, or vitamin E with L-carnitine. Verdict: a recommendation against on Grade B to C evidence, not a finding of harm — the grades follow below.

Penile traction therapy has the youngest evidence base here, so read it in time order. In 2018, reviewing 52 articles for Eur Urol, Russo and colleagues (PMID 30237020) found traction and vacuum benefits shown "only in small, underpowered, nonrandomised studies" — fair then. Moncada and colleagues (BJU Int 2019, PMID 30365247) then ran a controlled multicentre study of the PeniMaster PRO device in 93 men with stable disease and unidirectional curvature of at least 45 degrees: curvature fell a mean 31.2 degrees from baseline, a 41.1% improvement (p<0.001), with no significant change in the non-intervention group — and dose-dependently, 19.7 degrees below four hours of daily wear against 38.4 degrees above six. Joseph and colleagues (J Sex Med 2020, PMID 33223425) randomized 110 men 3:1 in a trial of the RestoreX device: 77% improved curvature. Pooling the device literature, Almsaoud and colleagues (Transl Androl Urol 2023, PMID 38106680) found significant curvature reduction (p=0.037) and no significant length change (p=0.53) — curvature, never length. Verdict: randomized and pooled support for curvature in stable disease, at a lower ceiling than surgery. Depth sits in penile traction for Peyronie's disease.

Surgery corrects more curvature than any other option in this comparison, and charges the most for it. The AUA grades tunical plication (Statement 18), plaque incision or excision and grafting (Statement 19), and penile prosthesis surgery (Statement 20) Moderate on Grade C evidence, in stable disease. In a retrospective review, Reddy and colleagues (J Sex Med 2018, PMID 30228083) reported penile curvature corrected in 91% of the operated cohort — with subjective shortening reported by 62.7% of the 102 men surveyed at a median 59.5 months. Rice and colleagues, reviewing 20 years of plaque incision and grafting (Sex Med 2019, PMID 30890446), found straightening in 80.0% to 96.4% of men across 12 studies — but 4.6% to 67.4% needing pharmacologically aided erections, with no consistent definition of success. Verdict: the highest correction ceiling, at the highest cost, for stable deformity only — technique belongs to the Peyronie's disease surgery guide.

Watchful waiting stays legitimate for mild, non-progressing disease that does not interfere with intercourse, reviewed with a urologist.

The five classes are compared below.

In short: collagenase holds the highest evidence grade in this comparison, surgery the highest correction ceiling, traction the lowest barrier to entry — verapamil a negative trial.

Penile traction therapy is the best-fit Peyronie's treatment in one specific case: the man who wants curvature correction without an operation and without a needle in the plaque — a stable, unidirectional curve that bothers him, erections adequate for intercourse, no appetite for surgery's trade-offs. What the evidence supports: curvature reduction tracks wear time. In the PeniMaster PRO study, men wearing the device more than six hours daily averaged 38.4 degrees of correction against 19.7 degrees below four hours — treatment compliance decides the outcome. Length is not the target: the pooled device literature found no significant change in penile length (Almsaoud 2023, PMID 38106680) — curvature is what traction is chosen for.

The limitation belongs in the same breath: Russo's 2018 systematic review in Eur Urol (PMID 30237020) described the mechanical-therapy evidence as underpowered. The trials cited here enrolled stable disease, so acute-phase use is a supervised decision. Once the lane is chosen, the question becomes which device — they differ in calibrated force, wear time, and disclosure, the job of the guide to the best traction device for Peyronie's disease.

In short: traction fits the stable, bothersome curve in a man refusing surgery and needles — in the PeniMaster PRO trial the outcome rose with hours worn.

Injections or surgery become the better Peyronie's treatment in two situations. The first is stable disease inside the range collagenase was studied in: curvature between 30 and 90 degrees, erections adequate for intercourse, and willingness to attend cycle-based appointments. For that patient the evidence is unmatched in this comparison — a Grade B guideline statement and a pooled post hoc 34% mean curvature improvement against 18.2% on placebo — so a supervised injection protocol is the rational first choice, with the corporeal-rupture risk discussed before consent.

The second is a severe or complex stable deformity — steep, hourglass, or biplanar enough that no conservative lane will straighten it. Surgery owns that case because its correction ceiling is higher than any other option in this comparison — 91% corrected but 62.7% reporting shortening in Reddy's plication series, and 80.0% to 96.4% straightened but 4.6% to 67.4% needing pharmacologically aided erections across the 12 grafting studies Rice reviewed. Both AUA surgical statements are written for stable disease, so the urologist who measured the curve makes this call with you.

In short: injections win the stable curve in the studied range, surgery the severe deformity — trade-offs accepted, not hidden.

Several widely marketed Peyronie's treatments already carry a guideline recommendation against them, the easiest part of the decision. AUA Guideline Statement 6 is explicit: "Clinicians should not offer oral therapy with vitamin E, tamoxifen, procarbazine, omega-3 fatty acids, or a combination of vitamin E with L-carnitine." The grades read agent by agent.

Vitamin E, alone or combined with L-carnitine

Recommended against on Grade B evidence — the most heavily marketed oral option.

Omega-3 fatty acids

Recommended against on Grade B evidence; cardiovascular arguments for fish oil do not transfer to a fibrous plaque.

Tamoxifen and procarbazine

Recommended against on Grade C evidence — prescription agents once used off-label.

"Should not offer" is a Moderate Recommendation against, not a finding of harm, and Statement 6 names only those five agents — it takes no position on the supplements sold beside them. Where a natural treatment for Peyronie's disease is under consideration, it belongs in the conversation with a urologist, weighed against the options you are choosing between.

In short: five oral agents carry a guideline recommendation against them; most of what is sold beside them has never been tested for penile curvature.

This evaluation sits inside the Peyronie's disease hub. These pages cover the condition, the traction lane, and the device choice.

A companion effectiveness-by-severity guide is still to come.